Unlocking ADAM28's Potential Therapeutic Applications (G10863)

Target Name: ADAM28

NCBI ID: G10863

ADAM28

Unlocking ADAM28's Potential Therapeutic Applications

Unlocking the Potential of ADAM28: A Dishonest Parasite-Induced Metal Toxicity and its Potential Therapeutic Applications

ADAM28, a disintegrin and metalloproteinase domain 28 (DMP28) gene located on chromosome 19, has been identified as a potential drug target and biomarker for various diseases. This gene has been associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of ADAM28 as a drug target has significant implications for the development of new treatments and therapies.

The DMP28 gene Family

The DMP28 gene family is a member of the superfamily of metal-dependent enzymes, known as the metal-dependent intracellular signaling (MIS) enzymes. These enzymes are involved in the regulation of various cellular processes, including cell signaling, DNA replication, and stress response. The DMP28 gene is characterized by the presence of a disintegrin and metalloproteinase domain (DMP28), which are unique features that enable the enzyme to induce metal toxicity and participate in various cellular processes.

ADAM28: A Potential Drug Target

The identification of ADAM28 as a potential drug target has significant implications for the development of new treatments and therapies. ADAM28 has been associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of ADAM28 as a drug target has the potential to lead to the development of new treatments for these diseases.

One of the potential benefits of targeting ADAM28 is its ability to induce metal toxicity, which can be used as a therapeutic approach in diseases characterized by metal toxicity, such as cancer, neurodegenerative diseases, and autoimmune disorders. The ability of ADAM28 to induce metal toxicity makes it an attractive candidate for targeting these diseases.

Another potential benefit of targeting ADAM28 is its role in the regulation of cellular processes, including cell signaling, DNA replication, and stress response. The DMP28 gene has been shown to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and stress response. Targeting ADAM28 may have the potential to modulate these cellular processes and lead to the development of new treatments for various diseases.

The Potential of ADAM28 as a Drug Target

The development of new treatments for various diseases depends on the identification of potential drug targets. ADAM28 has the potential to be a drug target for various diseases due to its association with the development of these diseases.

In the context of cancer, ADAM28 has been identified as a potential drug target due to its association with the development of various types of cancer, including breast, ovarian, and colorectal cancers. The ability of ADAM28 to induce metal toxicity may have the potential to inhibit the development of cancer cells by inhibiting the activity of cell signaling pathways that are dependent on metals.

In the context of neurodegenerative diseases, ADAM28 has been identified as a potential drug target due to its association with the development of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The ability of ADAM28 to induce metal toxicity may have the potential to inhibit the development of neurodegenerative diseases by modulating the cellular processes that are dependent on metals.

In the context of autoimmune disorders, ADAM28 has been identified as a potential drug target due to its association with the development of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. The ability of ADAM28 to

Protein Name: ADAM Metallopeptidase Domain 28

Functions: May play a role in the adhesive and proteolytic events that occur during lymphocyte emigration or may function in ectodomain shedding of lymphocyte surface target proteins, such as FASL and CD40L. May be involved in sperm maturation

The "ADAM28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAM28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets